Results 71 to 80 of about 8,055 (251)

Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques, João Pedro Stringhetta Rahal, Rafael da Cunha Gomes Ribeiro, Enzo Bogucheski Ribeiro Machado, Carlos Antonio Negrato   +4 more
wiley   +1 more source

Evaluating Tirzepatide\u27s Therapeutic Potential in Mitigating Obesity-Associated Comorbidities [PDF]

Objective: The study aims to explore the therapeutic potential of dual GIP/GLP-1 agonist tirzepatide in managing obesity and its associated manifestations, including obstructive sleep apnea (OSA), hidradenitis suppurativa (HS), and obesity-associated ...
Kahook, Zaneh, Bryan, Carina, Jones, Talaya, Parmar, Mayur   +3 more
core   +1 more source

Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis

BMC Endocrine Disorders
Objective The objective is to assess the effectiveness and safety of tirzepatide, liraglutide, and SGLT2i in individuals diagnosed with type 2 diabetes.
Yunjie Teng, Xue Fan, Rui Yu, Xiaoping Yang   +3 more
doaj   +1 more source

The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials

Pharmaceuticals
Background: Obesity and type 2 diabetes (T2D) are major public health concerns. Tirzepatide has shown promise in recent clinical trials. This systematic review and meta-analysis aim to evaluate the efficacy and safety of tirzepatide in adults with ...
Ligang Liu, Hekai Shi, Merilyn Xie, Yuxiao Sun, Milap C. Nahata   +4 more
doaj   +1 more source

Tirzepatide - A Revolution in Obesity Treatment? [PDF]

Introduction and aim of study: Obesity is a chronic disease associated with numerous health complications, and the number of patients is steadily increasing. Pharmacological methods for treating obesity are becoming increasingly popular.
Wojciechowska, Klara, Turek, Monika, Jaroń, Aleksandra, Chaberska, Iwona, Feruś, Aleksandra, Piątkowska, Karolina, Lipska, Julia, Jastrzębska, Katarzyna   +7 more
core  

SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity

Obesity, EarlyView.
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter, Julie Mount, J. Martin Gibson, Joanne Webb, Cheryl Marler, Catherine Reed, Mugdha Gore, Wenyu Ye, Elisa Gomez Valderas, John Wilding, Naveed Sattar, Melanie J. Davies, Kamlesh Khunti, Richard Haynes, Rachel L. Batterham   +14 more
wiley   +1 more source

Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta‐analysis

Journal of Diabetes Investigation
Objective To investigate the risk of biliary diseases in patients with type 2 diabetes mellitus (T2DM) or obesity treated with tirzepatide. Methods Literature searches were performed using the PubMed, Web of Science, Cochrane Library, and CNKI databases ...
Jie Gong, Fengwei Gao, Kangyi Jiang, Qingyun Xie, Xin Zhao, Zehua Lei   +5 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective To evaluate glucagon‐like peptide 1 receptor agonists for obstructive sleep apnea compared with controls. Data Sources CINAHL, Cochrane Library, PubMed, and Scopus. Review Methods A PRISMA‐compliant search was conducted from database inception through October 2025.
Cali Loblundo, Sammy Y. Gao, Shaun A. Nguyen, Mohamed Abdelwahab   +3 more
wiley   +1 more source

Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era. [PDF]

Endocrinol Diabetes Metab
Tirzepatide and SGLT2 inhibitors act through distinct but complementary mechanisms in obesity‐related HFpEF: tirzepatide targets adiposity, inflammation, and insulin resistance, while SGLT2 inhibitors improve decongestion, myocardial energetics, and cardiac remodeling.
Mohamed ZI, Shidane AA, Abdiasis AM, Hussein MH, Ibrahim AO, Abdi AA, Hashi KI, Mohamud MA, Mohamed AJ.   +8 more
europepmc   +2 more sources

The Tirzepatide Drop: Beware of Slimmer’s Paralysis

This case series explores the association between tirzepatide-assisted weight loss and the development of foot drop due to peroneal nerve neuropathy, a phenomenon known as slimmer’s paralysis.
John M. Tucker MD, Jordan Ritchie MD
core   +1 more source